

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



APPLICANTS: Wands et al  
SERIAL NUMBER: .09/872,968 EXAMINER: Not Yet Assigned  
FILING DATE: June 1, 2001 ART UNIT: 1646  
FOR: INHIBITION OF NEURODEGENERATION

Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination of the above-identified patent application, please amend the application as set forth below and consider the following remarks.

*In the Claims:*

Cancel claims 1-20 and 27-49.

REMARKS

Claims 21-26 and 50-52 are pending. Claims 1-20 and 27-49 were canceled as being drawn to the non-elected invention. No new matter has been added by this amendment.

CONCLUSION

On the basis of the foregoing amendments and remarks, Applicants submit that the pending claims are in condition for allowance. If there are any questions regarding these amendments and remarks, the Examiner is encouraged to contact either of the undersigned at the telephone number provided below.

The Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21486-047.

Respectfully submitted,

A handwritten signature in cursive script that reads "IA Beattie".

Ingrid A. Beattie, Reg. No. 42,306  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Dated: September 30, 2002

RECEIVED  
SEP 04 2002  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Wands et al  
SERIAL NUMBER: 09/872,968 EXAMINER: Not Yet Assigned  
FILING DATE: June 1, 2001 ART UNIT: 1646  
FOR: INHIBITION OF NEURODEGENERATION



Commissioner for Patents  
Washington, D.C. 20231


RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement (Paper 10) mailed on May 29, 2002, Applicants elect the invention of Group 2 (claims 21-26 and 50-52), drawn to a nontransgenic model for Alzheimer's Disease comprising a nonhuman animal comprising an exogenous AD7c-NTP nucleic acid and methods of identifying a compound using the animal. This election is made without traverse.

Applicant reserves the right to prosecute claims which are equal to or broader in scope in this, or future applications related to the above-identified patent application.

With the enclosed three-month extension, a response to this Office Action is due on or before September 30, 2002. Although Applicant believes no fee is due in connection with this filing, the Commissioner is hereby authorized to charge any fee that may be due to Deposit Account No. 50-0311 (Reference No. 21486-047).

Respectfully submitted,

  
Ingrid Beattie 42,306  
Attorneys for Applicants  
c/o MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY & POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241

RECEIVED

SEP 04 2002

TRA 1717128v1

TECH CENTER 1600/2900